Key takeaways:
Every so often a piece of research comes along that makes you stop and appreciate how far medicine has come. This is one of those.
Researchers just reported early results for a one-time treatment that durably lowers LDL cholesterol by editing a single gene. One infusion, with effects that have held for up to a year and a half so far, and likely to last a lifetime. It's very early research in a small, specific group of patients, and it's years from a doctor's office. But the underlying biology is some of the most well-studied in all of cardiovascular medicine, and it connects directly to your brain.
Editing one gene to lower cholesterol
The therapy, called VERVE-102, targets a gene called PCSK9. PCSK9 is a protein that reduces your liver's ability to clear LDL cholesterol from your blood. The more PCSK9 activity you have, the fewer LDL "receptors" your liver keeps available to pull LDL particles out of circulation.
Here's the reassuring part: some people are born with naturally low-functioning PCSK9 genes, and they tend to have markedly lower LDL across their entire lives, substantially lower rates of heart disease, and no apparent downside. Turning down PCSK9 is a protective pattern scientists have studied for two decades. We already have approved PCSK9-lowering drugs; they just require ongoing injections.
What's new is the delivery. VERVE-102 uses base editing, a precise form of gene editing, to make a single change to the PCSK9 gene in liver cells after one infusion, doing once, durably, what current drugs do repeatedly. In the Heart-2 trial, a single dose lowered LDL by an average of around 50%, and by as much as roughly 69% at the higher doses, with reductions holding for up to 18 months and no treatment-related serious adverse events reported.
The honest caveats
The headline is easy to over-read, so here's the careful version. It's a phase 1b trial, an early stage focused on safety and initial signals in a small number of participants, and it has not been shown to prevent heart attacks, strokes, or cognitive decline. It enrolled a specific, high-risk group (inherited very high cholesterol or early coronary artery disease), so these are not general-population results. And gene editing is genuinely new: the PCSK9 mechanism is exceptionally well understood, but a permanent edit to a gene is a young field whose long-term safety story takes years to write. The likely path is approval first for very high-risk individuals, at significant cost, after a larger phase 2 trial.
Why this is a brain-health story
At BetterBrain, we look at the whole body, because your brain doesn't exist in isolation from it, and few things connect the two as directly as lipids.
Start with ApoB. You've probably heard of LDL cholesterol; ApoB is the more precise number underneath it. Every LDL particle carries exactly one ApoB protein, so LDL-C tells you the amount of cholesterol in LDL particles, while ApoB tells you the number of particles actually driving damage in your artery walls. When the two disagree, ApoB is the better predictor of risk. Lowering PCSK9, through these new therapies or the drugs we already have, lowers both.
Now connect it to the brain. The blood vessels that feed your brain face the same lipid-driven damage as the ones feeding your heart, and that vascular damage is one of the major pathways of cognitive decline. Protecting your lipids over a lifetime is protecting your brain, especially for people who tend to run higher LDL, including APOE4 carriers. That's one reason lipid management is a core part of what we do.
What this means for you, right now
You don't have to wait for a therapy that's years away. The target itself, your lipid health, is something you can measure and move today.
Get your ApoB tested, not just standard cholesterol, because it counts the particles actually driving damage. Think of lipids as a lifelong number: it's the decades of cumulative exposure that drive risk, so small, steady improvements compound in your favor, and starting earlier beats starting perfectly. Use the levers you already have, including diet, regular movement, and, where your physician recommends them, proven medications.
If you'd like to see where you stand, BetterBrain Blueprint covers ApoB and 50+ other markers and starts at $89 with insurance, and a BetterBrain coach can pull your full lipid picture into one clear plan, so that whatever arrives in five or ten years, you've protected the decades in between.